Pharvaris has announced the start of enrollment in CHAPTER-3, a Phase 3 study assessing the efficacy of deucrictibant for preventing hereditary angioedema (HAE) attacks, with topline results expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback